近日,中财瀚熙(北京)生物科技发展有限公司汪国鹏老师团队,使用IPHASE品牌产品:IPHASE NADPH Regeneration System在《FRONTIERS IN PHARMACOLOGY》权威期刊上发表文章《Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling》,影响因子5.6!
This study aimed to apply a physiologically based pharmacokinetic (PBPK) model to predict optimal dosing regimens of pazopanib (PAZ) for safe and effective administration when co-administered with CYP3A4 inhibitors, acid reducing agents, food, and administered in patients with hepatic impairment. Here, we have successfully developed the population PBPK model and the predicted PK variables by this model matched well with the clinically observed data.
In summary, the present PBPK model can determine the optimal dosing adjustment recommendations in multiple clinical uses, which cannot be achieved by only focusing on AUC linear change of PK.